Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1

 

Pluvicto®

Pluvicto® is the first and only approved PSMA-targeted radioligand therapy (RLT) in the United Kingdom (UK) and is available to eligible private patients in the UK.1

Icon of an arrow on the bulls-eye of a target.

Pluvicto mechanism of action

Show more about Pluvicto mechanism of action

 

Icon of a magnifying glass.

 

Icon representing intravenous administration of Pluvicto.

Dosing and administration

Read more about dosing and administration

 

Email icon.

If you have any further questions, contact us.

Click here to contact us

 

The most common (≥20%) adverse drug reactions (ADRs) occurring at a higher incidence in patients who received Pluvicto + BSoC compared to BSoC alone include fatigue, dry mouth, nausea, anaemia, decreased appetite and constipation. The most common grade 3 to 4 ADRs (≥5%) occurring at a higher incidence in patients who received Pluvicto plus BSoC compared to BSoC alone include: anaemia (12.9%), thrombocytopenia (7.9%), lymphopenia (7.8%) and fatigue (5.9%).1

 

177Lu, lutetium; ADR, adverse drug reaction; AR, androgen receptor; BSoC, best standard of care; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy.

References:

  1. Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics.
  2. Sartor O, et al. N Engl J Med 2021;385(12):1091–1103.

 

UK | FA-11331025 | February 2025
×

Ask Speakers

×

Medical Information Request